Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.62 |
| ▸ | FAP | Q12884 | 6/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.52 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16104907 | 1.00 | DPP4 (0.67) | DPP4HDAC2FAPDPP8DPP9 | |
| SCHEMBL3179037 | 1.00 | DPP4 (0.67) | DPP4HDAC2FAPDPP8DPP9 | |
| SCHEMBL8287953 | 0.81 | HRH3 (0.56) | DPP4FAPDPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL6181888 | 0.79 | DPP4 (0.98) | DPP4HDAC2FAPDPP8 | |
| Hydrochloric Acid SCHEMBL6185505 | 0.79 | DPP4 (0.98) | DPP4HDAC2FAPDPP8 | |
| SCHEMBL13347244 | 0.79 | DPP4 (0.70) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL8285601 | 0.79 | DPP4 (0.70) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL13347125 | 0.78 | DPP4 (0.65) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL3195160 | 0.78 | DPP4 (0.65) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL13347199 | 0.78 | DPP4 (0.50) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7674913-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1997533-A1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | Phenomix Corporation (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2005047297-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120661-A1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | DPP4, DPP7, DPP3 | DPP4 1/4885HDAC2 405/4885FAP 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.